Nuclear MRI(NMR)in Women at Risk of Fracture Receiving Either Zoledronic Acid or Teriparatide



Status:Archived
Conditions:Osteoporosis, Gastrointestinal
Therapuetic Areas:Gastroenterology, Rheumatology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:July 2008
End Date:December 2012

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

NMR Imaging and Stereological Analysis of Trabecular Bone in Female Subjects 60 and Older at Risk of Fracture Receiving Either Zoledronic Acid or Teriparatide


The purpose of this study is to determine the changes in trabecular bone architecture in
women 60 and older with high risk of fracture treated with either teriparatide or zoledronic
acid.


The overall design is to determine and compare the effect of teriparatide and of zoledronic
acid on trabecular architecture by magnetic resonance microimaging of the midshaft tibia.
Fifty-six postmenopausal women, aged 60 or older with osteoporosis and/or at increased risk
of fracture, will be randomized to receive either teriparatide or zoledronic acid. Both
groups will be followed for 24 months. Trabecular microarchitecture, cortical structural
parameters, biomechanical parameters and bone mineral density will be examined at 0, 12, and
24 months.


We found this trial at
1
site
Hospital of the University of Pennsylvania
3400 Spruce St
Philadelphia, Pennsylvania 19104
 (215) 662-4000
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials